Redeye updates its estimates and fair value range for Enviro following the final investment decision...
Sales +7% vs. ABGSCe, EBIT +18% vs. ABGSCe Organic growth of +3%, better than ABGSCe -5% Order booki...
Redeye provides its initial comments on Catella's Q4 2023 report, which came in below our forecasts.
Q4 EBIT of SEK 8m vs. ABGSC at 57m and cons. at SEK 66m AUM down 4% q-o-q, driven by FX and negative...
G5 reported weaker than expected growth in Q4 2023 and while recent and upcoming game launches suppo...
Q4 sales +41% y-o-y, +6% vs ABGSCe 111 units started units, 1,182 units in ongoing production GP mar...
Redeye comments on Maximum Entertainment ahead of its Q4-results (due 15 February) where we expect s...
We lower '23e-'25e adj. EBITA by 6-2% Q4 macro data slightly worse than Q3 '24e EV/EBITA of just bel...
Redeye provides its view of Active Biotech's fourth quarter report of 2023 and updates it base case.
Fiskars' Q4 was bang in line with consensus expectations (LSEG Data & Analytics).
Redeye maintains its positive view of Transtema following a Q4 showing a better q/q margin improveme...
Redeye is revising its forecasts on the back of a somewhat weaker market outlook and Powercell’s cur...
Redeye adjusts its base case in light of the recent right issue.
- Soft NOI margin, higher financials, rec PTP -13% vs ABGSCe - Value changes of -2.
Redeye updates its view of IRLAB following the Q4 report and largely reiterate our previous view.
- Sales +1% vs. ABGSCe, EBIT +10% on better GM - Expects sales to decline H1'24 but recover well in ...
Fjärde Kvartalet Omsättningen var +4% y/y, 271 mkr (261), varav 3% organisk och 1% valuta.
Redeye is encouraged to see another quarter with strong sales growth of 25% Y/Y with business projec...
- Sales +15% y-o-y, +13% vs. ABGSCe - Underlying operating profit well above ABGSCe - Expect cons to...
Redeye is positively surprised by last night’s press release from Enviro, stating that a final inves...
